Regulation of immune function by calorie restriction and cyclophosphamide treatment in lupus-prone NZB/NZW F1 mice

Cellular Immunology

Volumn 228, Issue 1, 2004, Pages 54-65

  Sun, Dongxu ^a   Krishnan, Aparna ^a   Su, Jianrong ^a   Lawrence, Richard ^a   Zaman, Khaliquz ^a   Fernandes, Gabriel ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Calorie restriction; Cyclophosphamide; Cytokines; SLE; T cells

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA; HISTONE ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN ANTIBODY COMPLEX; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; CALORIC RESTRICTION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; DRUG INHIBITION; FEMALE; IMMUNOREGULATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; RECEPTOR UPREGULATION;

ANIMALS; ANTIBODIES, ANTINUCLEAR; ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; B-LYMPHOCYTES; CALORIC RESTRICTION; CD4-CD8 RATIO; CYCLOPHOSPHAMIDE; DNA; FEMALE; HISTOCOMPATIBILITY ANTIGENS; HISTONES; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED NZB; MICE, INBRED STRAINS; SPLEEN; T-LYMPHOCYTES; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 2942618696     PISSN: 00088749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cellimm.2004.04.001     Document Type: Article

References (64)

1. Wofsy D., Seaman W.E. Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. J. Exp. Med. 161:1985;378-391
2. Asanuma Y., Oeser A., Shintani A.K., Turner E., Olsen N., Fazio S., Linton M.F., Raggi P., Stein C.M. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349:2003;2407-2415
3. Roman M.J., Shanker B.A., Davis A., Lockshin M.D., Sammaritano L., Simantov R., Crow M.K., Schwartz J.E., Paget S.A., Devereux R.B., Salmon J.E. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349:2003;2399-2406
4. Theofilopoulos A.N., Dixon F.J. Murine models of systemic lupus erythematosus. Adv. Immunol. 37:1985;269-390
5. James M.J., Cleland L.G. Dietary n-3 fatty acids and therapy for rheumatoid arthritis. Semin. Arthritis Rheum. 27:1997;85-97
6. Fernandes G., Friend P., Yunis E.J., Good R.A. Influence of dietary restriction on immunologic function and renal disease in (NZB. × NZW) F1 mice Proc. Natl. Acad. Sci. USA. 75:1978;1500-1504
7. Jolly C.A., Muthukumar A., Avula C.P., Troyer D., Fernandes G. Life span is prolonged in food-restricted autoimmune-prone (NZB. × NZW)F(1) mice fed a diet enriched with (n-3) fatty acids J. Nutr. 131:2001;2753-2760
8. Fernandes G., Yunis E.J., Good R.A. Influence of diet on survival of mice. Proc. Natl. Acad. Sci. USA. 73:1976;1279-1283
9. Fernandes G., Good R.A. Inhibition by restricted-calorie diet of lymphoproliferative disease and renal damage in MRL/lpr mice. Proc. Natl. Acad. Sci. USA. 81:1984;6144-6148
10. Jolly C.A., Muthukumar A., Reddy Avula C.P., Fernandes G. Maintenance of NF-kappaB activation in T-lymphocytes and a naive T-cell population in autoimmune-prone (NZB/NZW)F(1) mice by feeding a food-restricted diet enriched with n-3 fatty acids. Cell. Immunol. 213:2001;122-133
11. Daikh D.I., Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J. Immunol. 166:2001;2913-2916
12. Casey T.P. Immunosuppression by cyclophosphamide in NZB. × NZW mice with lupus nephritis Blood. 32:1968;436-444
13. Gelfand E.W., Berkel A.I., Godwin H.A., Rocklin R.E., David J.R., Rosen F.S. Pernicous anaemia, hypogammaglobulinaemia, and altered lymphocyte reactivity. A family study. Clin. Exp. Immunol. 11:1972;187-199
14. Takeno M., Suzuki N., Nagafuchi H., Mizushima Y., Sakane T. Selective suppression of resting B cell function in patients with systemic lupus erythematosus treated with cyclophosphamide. Clin. Exp. Rheumatol. 11:1993;263-270
15. Ozer H., Cowens J.W., Colvin M., Nussbaum-Blumenson A., Sheedy D. In vitro effects of 4-hydroperoxycyclophosphamide on human immunoregulatory T subset function. I. Selective effects on lymphocyte function in T-B cell collaboration. J. Exp. Med. 155:1982;276-290
16. Gladstone D.E., Prestrud A.A., Pradhan A., Styler M.J., Topolsky D.L., Crilley P.A., Hoch S., Huppert A., Brodsky I. High-dose cyclophosphamide for severe systemic lupus erythematosus. Lupus. 11:2002;405-410
17. Bhattacharya A., Lawrence R.A., Krishnan A., Zaman K., Sun D., Fernandes G. Effect of dietary n-3 and n-6 oils with and without food restriction on activity of antioxidant enzymes and lipid peroxidation in livers of cyclophosphamide treated autoimmune-prone NZB/W female mice. J. Am. Coll. Nutr. 22:2003;388-399
18. Jolly C., Muthukumar A., Reddy Avula C., Troyer D., Fernandes G. Life span is prolonged in food-restricted autoimmune-prone (NZB. × NZW)F(1) mice fed a diet enriched with (n-3) fatty acids J. Nutr. 131:2001;2753-2760
19. Jolly C.A., Fernandes G. Diet modulates Th-1 and Th-2 cytokine production in the peripheral blood of lupus-prone mice. J. Clin. Immunol. 19:1999;172-178
20. Muthukumar A., Zaman K., Lawrence R., Barnes J.L., Fernandes G. Food restriction and fish oil suppress atherogenic risk factors in lupus prone (NZB. × NZW)F1 mice J. Clin. Immunol. 23:2003;23-33
21. Diamond B., Katz J.B., Paul E., Aranow C., Lustgarten D., Scharff M.D. The role of somatic mutation in the pathogenic anti-DNA response. Annu. Rev. Immunol. 10:1992;731-757
22. Yoshida S., Castles J.J., Gershwin M.E. The pathogenesis of autoimmunity in New Zealand mice. Semin. Arthritis Rheum. 19:1990;224-242
23. Mohan C., Shi Y., Laman J.D., Datta S.K. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J. Immunol. 154:1995;1470-1480
24. Reininger L., Winkler T.H., Kalberer C.P., Jourdan M., Melchers F., Rolink A.G. Intrinsic B cell defects in NZB and NZW mice contribute to systemic lupus erythematosus in (NZB. × NZW)F1 mice J. Exp. Med. 184:1996;853-861
25. Ando D.G., Sercarz E.E., Hahn B.H. Mechanisms of T and B cell collaboration in the in vitro production of anti-DNA antibodies in the NZB/NZW F1 murine SLE model. J. Immunol. 138:1987;3185-3190
26. Sekigawa I., Okada T., Noguchi K., Ueda G., Hirose S., Sato H., Shirai T. Class-specific regulation of anti-DNA antibody synthesis and the age-associated changes in (NZB. × NZW)F1 hybrid mice J. Immunol. 138:1987;2890-2895
27. Kammer G.M., Stein R.L. T lymphocyte immune dysfunctions in systemic lupus erythematosus. J. Lab. Clin. Med. 115:1990;273-282
28. Stohl W., Elliott J.E., Hamilton A.S., Deapen D.M., Mack T.M., Horwitz D.A. Impaired recovery and cytolytic function of CD56+ T and non-T cells in systemic lupus erythematosus following in vitro polyclonal T cell stimulation. Studies in unselected patients and monozygotic disease-discordant twins. Arthritis Rheum. 39:1996;1840-1851
29. Horwitz D.A., Gray J.D., Behrendsen S.C., Kubin M., Rengaraju M., Ohtsuka K., Trinchieri G. Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus. Arthritis Rheum. 41:1998;838-844
30. Svenungsson E., Fei G.Z., Jensen-Urstad K., de Faire U., Hamsten A., Frostegard J. TNF-alpha: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. Lupus. 12:2003;454-461
31. Mehrian R., Quismorio F.P. Jr., Strassmann G., Stimmler M.M., Horwitz D.A., Kitridou R.C., Gauderman W.J., Morrison J., Brautbar C., Jacob C.O. Synergistic effect between IL-10 and bcl-2 genotypes in determining susceptibility to systemic lupus erythematosus. Arthritis Rheum. 41:1998;596-602
32. Llorente L., Zou W., Levy Y., Richaud-Patin Y., Wijdenes J., Alcocer-Varela J., Morel-Fourrier B., Brouet J.C., Alarcon-Segovia D., Galanaud P., Emilie D. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J. Exp. Med. 181:1995;839-844
33. Zhang X., Fujii H., Kishimoto H., LeRoy E., Surh C.D., Sprent J. Aging leads to disturbed homeostasis of memory phenotype CD8(+) cells. J. Exp. Med. 195:2002;283-293
34. high lymphocytes accumulate with age in mice and respond poorly to concanavalin-A. Eur. J. Immunol. 19:1989;977-982
35. Engwerda C.R., Fox B.S., Handwerger B.S. Cytokine production by T lymphocytes from young and aged mice. J. Immunol. 156:1996;3621-3630
36. Liossis S.N., Ding X.Z., Dennis G.J., Tsokos G.C. Altered pattern of TCR/CD3-mediated protein-tyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T cell receptor zeta chain. J. Clin. Invest. 101:1998;1448-1457
37. Linker-Israeli M., Bakke A.C., Kitridou R.C., Gendler S., Gillis S., Horwitz D.A. Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). J. Immunol. 130:1983;2651-2655
38. Murakawa Y., Takada S., Ueda Y., Suzuki N., Hoshino T., Sakane T. Characterization of T lymphocyte subpopulations responsible for deficient interleukin 2 activity in patients with systemic lupus erythematosus. J. Immunol. 134:1985;187-195
39. Mishra N., Brown D.R., Olorenshaw I.M., Kammer G.M. Trichostatin A reverses skewed expression of CD154, interleukin-10, and interferon-gamma gene and protein expression in lupus T cells. Proc. Natl. Acad. Sci. USA. 98:2001;2628-2633
40. Desai-Mehta A., Lu L., Ramsey-Goldman R., Datta S.K. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J. Clin. Invest. 97:1996;2063-2073
41. al-Janadi M., al-Balla S., al-Dalaan A., Raziuddin S. Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases. J. Clin. Immunol. 13:1993;58-67
42. Tokano Y., Morimoto S., Kaneko H., Amano H., Nozawa K., Takasaki Y., Hashimoto H. Levels of IL-12 in the sera of patients with systemic lupus erythematosus (SLE)-relation to Th1- and Th2-derived cytokines. Clin. Exp. Immunol. 116:1999;169-173
43. Howard M., O' Garra A. Biological properties of interleukin 10. Immunol. Today. 13:1992;198-200
44. de Waal Malefyt R., Yssel H., de Vries J.E. Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J. Immunol. 150:1993;4754-4765
45. Llorente L., Richaud-Patin Y., Wijdenes J., Alcocer-Varela J., Maillot M.C., Durand-Gasselin I., Fourrier B.M., Galanaud P., Emilie D. Spontaneous production of interleukin-10 by B lymphocytes and monocytes in systemic lupus erythematosus. Eur. Cytokine Netw. 4:1993;421-427
46. Ishida H., Muchamuel T., Sakaguchi S., Andrade S., Menon S., Howard M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J. Exp. Med. 179:1994;305-310
47. Dauphinee M.J., Kipper S.B., Wofsy D., Talal N. Interleukin 2 deficiency is a common feature of autoimmune mice. J. Immunol. 127:1981;2483-2487
48. Altman A., Theofilopoulos A.N., Weiner R., Katz D.H., Dixon F.J. Analysis of T cell function in autoimmune murine strains. Defects in production of responsiveness to IL-2. J. Exp. Med. 154:1981;791-808
49. Jain J., Loh C., Rao A. Transcriptional regulation of the IL-2 gene. Curr. Opin. Immunol. 7:1995;333-342
50. Granelli-Piperno A., Nolan P. Nuclear transcription factors that bind to elements of the IL-2 promoter. Induction requirements in primary human T cells. J. Immunol. 147:1991;2734-2739
51. McGuire K.L., Iacobelli M. Involvement of Rel, Fos, and Jun proteins in binding activity to the IL-2 promoter CD28 response element/AP-1 sequence in human T cells. J. Immunol. 159:1997;1319-1327
52. Diamond M.S., Staunton D.E., de Fougerolles A.R., Stacker S.A., Garcia-Aguilar J., Hibbs M.L., Springer T.A. ICAM-1 (CD54): a counter-receptor for Mac-1 (CD11b/CD18). J. Cell Biol. 111:1990;3129-3139
53. Yung R., Powers D., Johnson K., Amento E., Carr D., Laing T., Yang J., Chang S., Hemati N., Richardson B. Mechanisms of drug-induced lupus. II. T cells overexpressing lymphocyte function-associated antigen 1 become autoreactive and cause a lupus like disease in syngeneic mice. J. Clin. Invest. 97:1996;2866-2871
54. Kaplan M.J., Beretta L., Yung R.L., Richardson B.C. LFA-1 overexpression and T cell autoreactivity: mechanisms. Immunol. Invest. 29:2000;427-442
55. Vratsanos G.S., Jung S., Park Y.M., Craft J. CD4(+) T cells from lupus-prone mice are hyperresponsive to T cell receptor engagement with low and high affinity peptide antigens: a model to explain spontaneous T cell activation in lupus. J. Exp. Med. 193:2001;329-337
56. Vyse T.J., Kotzin B.L. Genetic susceptibility to systemic lupus erythematosus. Annu. Rev. Immunol. 16:1998;261-292
57. Wakeland E.K., Wandstrat A.E., Liu K., Morel L. Genetic dissection of systemic lupus erythematosus. Curr. Opin. Immunol. 11:1999;701-707
58. Matsumoto Y., Hara N., Tanaka R., Fujiwara M. Immunohistochemical analysis of the rat central nervous system during experimental allergic encephalomyelitis, with special reference to Ia-positive cells with dendritic morphology. J. Immunol. 136:1986;3668-3676
59. Londei M., Lamb J.R., Bottazzo G.F., Feldmann M. Epithelial cells expressing aberrant MHC class II determinants can present antigen to cloned human T cells. Nature. 312:1984;639-641
60. Teyton L., Lotteau V., Turmel P., Arenzana-Seisdedos F., Virelizier J.L., Pujol J.P., Loyau G., Piatier-Tonneau D., Auffray C., Charron D.J. HLA DR, DQ, and DP antigen expression in rheumatoid synovial cells: a biochemical and quantitative study. J. Immunol. 138:1987;1730-1738
61. Bottazzo G.F., Dean B.M., McNally J.M., MacKay E.H., Swift P.G., Gamble D.R. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N. Engl. J. Med. 313:1985;353-360
62. Adelman N.E., Watling D.L., McDevitt H.O. Treatment of (NZB. × NZW)F1 disease with anti-I-A monoclonal antibodies J. Exp. Med. 158:1983;1350-1355
63. Jevnikar A.M., Grusby M.J., Glimcher L.H. Prevention of nephritis in major histocompatibility complex class II-deficient MRL-lpr mice. J. Exp. Med. 179:1994;1137-1143
64. Singer D.S., Zinger H., Kohn L.D., Mozes E. Differing MHC class I requirements for induction and propagation of experimental systemic lupus erythematosus. Eur. J. Immunol. 29:1999;2259-2268